0000950170-24-032535.txt : 20240318 0000950170-24-032535.hdr.sgml : 20240318 20240318083511 ACCESSION NUMBER: 0000950170-24-032535 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 11 CONFORMED PERIOD OF REPORT: 20240315 ITEM INFORMATION: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing FILED AS OF DATE: 20240318 DATE AS OF CHANGE: 20240318 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ATOSSA THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001488039 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 264753208 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35610 FILM NUMBER: 24757009 BUSINESS ADDRESS: STREET 1: 107 SPRING STREET CITY: SEATTLE STATE: WA ZIP: 98104 BUSINESS PHONE: 206.588.0256 MAIL ADDRESS: STREET 1: 107 SPRING STREET CITY: SEATTLE STATE: WA ZIP: 98104 FORMER COMPANY: FORMER CONFORMED NAME: ATOSSA GENETICS INC DATE OF NAME CHANGE: 20100325 8-K 1 atos-20240315.htm 8-K 8-K
0001488039false00014880392024-03-152024-03-15

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 15, 2024

 

 

Atossa Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-35610

26-4753208

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

107 Spring Street

 

Seattle, Washington

 

98104

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (206) 588-0256

 

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, $0.18 par value

 

ATOS

 

The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On March 15, 2024, Atossa Therapeutics, Inc. (the “Company”) received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that it had regained compliance with the minimum closing bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market.

As previously disclosed, on September 26, 2023, the Company was notified by Nasdaq that it was not in compliance with Nasdaq Listing Rule 5550(a)(2) because its common stock failed to maintain a minimum closing bid price of $1.00 per share for 30 consecutive business days. The Company was initially given until On March 25, 2024 to regain compliance.

To regain compliance, the Company was required to maintain a minimum closing bid price of $1.00 per share for at least 10 consecutive trading days. This requirement was met on March 14, 2024. As a result, the Company’s common stock will continue to be listed and traded on The Nasdaq Capital Market.

* * *

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

Atossa Therapeutics, Inc.

 

 

 

 

Date:

March 18, 2024

By:

/s/ Heather Rees

 

 

 

Heather Rees
Senior Vice President, Finance & Accounting

 

 EX-101.SCH 2 atos-20240315.xsd XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 100000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink Document Transition Report Document Information [Table] Pre-commencement Issuer Tender Offer Entity Address, State or Province Trading Symbol Soliciting Material Entity Address, City or Town Written Communications Entity Central Index Key Entity Tax Identification Number Entity Registrant Name Document Period End Date Entity Address, Postal Zip Code Entity Incorporation, State or Country Code Local Phone Number City Area Code Document Information [Line Items] Pre-commencement Tender Offer Security Exchange Name Entity Emerging Growth Company Amendment Flag Entity File Number Entity Address, Address Line One Title of 12(b) Security Document Type XML 4 R1.htm IDEA: XBRL DOCUMENT v3.24.1
Document And Entity Information
Mar. 15, 2024
Document Information [Line Items]  
Entity Registrant Name Atossa Therapeutics, Inc.
Document Type 8-K
Document Period End Date Mar. 15, 2024
Entity Incorporation, State or Country Code DE
Entity File Number 001-35610
Entity Tax Identification Number 26-4753208
Entity Address, Address Line One 107 Spring Street
Entity Address, City or Town Seattle
Entity Address, State or Province WA
Entity Address, Postal Zip Code 98104
City Area Code 206
Local Phone Number 588-0256
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Title of 12(b) Security Common Stock
Trading Symbol ATOS
Security Exchange Name NASDAQ
Amendment Flag false
Entity Central Index Key 0001488039
EXCEL 5 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 6 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 7 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 9 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1 html 1 22 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document And Entity Information Sheet http://atossatherapeutics.com/20240315/taxonomy/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false All Reports Book All Reports atos-20240315.htm atos-20240315.xsd http://xbrl.sec.gov/dei/2023 false false JSON 11 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "atos-20240315.htm": { "nsprefix": "atos", "nsuri": "http://atossatherapeutics.com/20240315", "dts": { "inline": { "local": [ "atos-20240315.htm" ] }, "schema": { "local": [ "atos-20240315.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 25, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://atossatherapeutics.com/20240315/taxonomy/role/statement-document-and-entity-information", "longName": "100000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_be0e5f16-e28a-462b-8541-3d0e2aabcfb8", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "atos-20240315.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_be0e5f16-e28a-462b-8541-3d0e2aabcfb8", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "atos-20240315.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://atossatherapeutics.com/20240315/taxonomy/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://atossatherapeutics.com/20240315/taxonomy/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationLineItems", "presentation": [ "http://atossatherapeutics.com/20240315/taxonomy/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationTable", "lang": { "en-us": { "role": { "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://atossatherapeutics.com/20240315/taxonomy/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://atossatherapeutics.com/20240315/taxonomy/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r6" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://atossatherapeutics.com/20240315/taxonomy/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://atossatherapeutics.com/20240315/taxonomy/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://atossatherapeutics.com/20240315/taxonomy/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://atossatherapeutics.com/20240315/taxonomy/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://atossatherapeutics.com/20240315/taxonomy/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://atossatherapeutics.com/20240315/taxonomy/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://atossatherapeutics.com/20240315/taxonomy/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://atossatherapeutics.com/20240315/taxonomy/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://atossatherapeutics.com/20240315/taxonomy/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://atossatherapeutics.com/20240315/taxonomy/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://atossatherapeutics.com/20240315/taxonomy/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://atossatherapeutics.com/20240315/taxonomy/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://atossatherapeutics.com/20240315/taxonomy/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://atossatherapeutics.com/20240315/taxonomy/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://atossatherapeutics.com/20240315/taxonomy/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://atossatherapeutics.com/20240315/taxonomy/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://atossatherapeutics.com/20240315/taxonomy/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://atossatherapeutics.com/20240315/taxonomy/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://atossatherapeutics.com/20240315/taxonomy/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r7" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 12 0000950170-24-032535-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-24-032535-xbrl.zip M4$L#!!0 ( &5$ 1 871OE#LU2EZSUXAZ2FZLR7/K(E$\US[+3L M )E?WU>R'1)>0EB21X!0"R1:K^Y^=27M__VVGZ!K+G.1I0<_&PWR,^)IE#&1 M7AW\?-0Y;K=__OOA#_M_P1B=G+7/T3F_04=1(:[YB5H@C'I%,6@UFS2 M4_4].J$%1RV3F#8F%C;\+C%:CM&RW$9@VO9_$](B9*)9-AA)<=4KT':T@U0K M&#M->9*,T)E(:1H)FJ!./>@NS#)JH*,D09>J58XN><[E-6>-LL]> R MK\E7+8R#B8\MH^Z'%MD=,:D/.2UZ7-(!!YJ,2CY0A$LLPYD8>_9$'QK8-#$Q ML>'6G0P+.1?:H FE6X<_H/T>IPQ^H_U"% D_]/%O^\WR3_5EGQ=4LS#F_QZ* MZX.MXRPM@+%Q%["XA:+RT\%6P6^+IF:,INJT6?6Z'V9LA/)BE/"#K3Z55R)M M(3HLLK^(_B"3@,EB;T"9DC8MY ]N][;TJ$Q&P;'M\1@'CNEC-[9# MQ^(PV3B>G.D1B%:FQ.M90J^>-4-4TLW!%A!:*Q:WG.&8)B A#O6O;V;=G%YK MR6,N04WP_'!?28M6KID39H"T]&@I'C_8R@')B>)4_5U/J@DJ!L UN3=NRP>JJ9<8[;^))CZ' LND9XVG\GAQ^W?IO%X MO_%A_=5T[P-8L(S5GT!6R4)IM,.Q0G/J=G=EXVFR.57KDOIS/4AS:FGJ=1PO M7'."69K 4_=YJR]2W.-*#[9(PQ&IXJ]QO4%=*\PD]("+;- R&Z8S*!#+AF'" MT8]$_^S%,#S.Q?_SED$&Q5[)YKI^51;3ODA&K:[H\UP;$)=9GZ9UQ3 KBJP/ M=14,F";B*FTE/"[4;/(!3>MYW/1$P3%\$_'60')\ R+T_M@/#@=CW0A6](#@ M"UQ)+ACDIQ\-E^SM-]58 /]@&OKYP#D-SUDTY'P((QBG?]RBHXO/G]N=SKMBW-=K5ZU)<)@/A.&/XXZO[;/?^E>G.^BD\9Q XQ! MQP[FH;7"C**SEDW^MC0:KIBE_JQ)!('-*]B87:HFVFK58[\QNE\\X!NA^K.+ MR\]H%@4_H>^MV1J=NK81A1[%L1M%V(ZY@VELQIB91AS;+#89,9^GN.^L@-K' MTI;86BRHMATKN3P][Z++TR\7E]U5KX,+M==U M);X,93X$CP@5&>KP2$=## ME$AG.-MM!68S <51%0RD* 7V>WD8]FEYQ%9%1 MQ49@V?=6L*#*5)LVY10LRN,"HE"E&/RK;%CY 7OES Q"&L 350-8D(0.6_C]67\Q@X/O#5ZYF*5 :Q "3]YI+\,)I4C6$$D4-CZ"[ MIPFD*6D#0YN![QH3/S"3E9#E/%K343:@F$NNW'"T77_F%!P*GA>(7ZOPG=3% MG.VTIA3E;*476]0T7=O"EAD3;)/ QJ%I.-CC2H/%H4-#NBRE]T5[0*>E7S3M MSC+X!O=AE)YJAAD=X1& A7FZPO7\3&74 S[=U3'(Q5H0R)Y-T3_\5KSX7/7X M5$_D RC(]^U\+EO[WPUEVL^S>0T:\#B(?,QI$(+-2PBF41SCT'.(X1N(H]T8!=U)R*[Y6;#$RWB^2BWULO@\QH+ M:7#.4FV?WE*P5Q162Q548Q/1''4&/%+Q-89$BMI%CHY[%#20W'FY"_%4BWDC M(]=81JZC76O>F;4SC-X'RAYNZ#]0:!O?V9*&15!X.-BRME[?JIXKXN;L"/D^ M"SW7PI'%8] VGH6I:1B8F4'('.KSV F7HZ% \&<23&>]-=[ZU%N2,7(F$@YCAURN$&V$P#0"M2V_;U69>I-ETY4@T76Q[CF42_QG^X0RI[JVK M4"]-P^63S"J0LJVELPJR7:BL#/3/H10Y$SKZIK>XP$*=DN8[J^2U-[5RQUF_ M+W*5.(:4$$0E VW6IUZ?]F4'G?8'23;B4I/2M+Q!YUECYF+-8OEW$@9=B("9 M<#[:,7@KNF\#[0;:#;1/LW8V/JPVD$UJQCZS/,R)!<:N$YLX]*B!O8Z(W5]^649 M_#$C0/C:_.*%/HFC.,!^P /@%X?C@/@N#D*7$8LXL4.\I?++,?QY(;O9S2K# M.!U.BR)9%,59U>B[C]@,#KR(<3^P,05_'ML!L;#/8#6I97K$" +;\*VEKKOV MXR[D%YE="WT^X/6";'_0O ?,4H '^8;#-8\.\:_:J"DGMX[")0YMAUH>PX1; M*LW/<'# H@@S.PPLYKO$,%^<\3!%Y%\RH.+D?\5 QY%71\&!;Y#G9#%LHE0K MBB54^%?[I5_ 2(K$@";H])9'0W44#UW$L8AXOM+8R]NPB#YDI D$ E(2X<%P MTLP,H\W6\(=*>31,Y^/F/-XEFOSTHV\:WEZ.NCSA@UZ6UL%KG;*3#-6*H2-8 M9LU5K6?:T_/F,?/,P5+EP6+S/(HCQES3!\O%M+ =4?"( F)CRXVI&1N<&;;_ M4LM%>4)J$5=LJYC$?24_:&>5A#$OR2X,8BN 1?;0.Q+]FB:-G MF03!@,YUYJA$U0C\2T714 ME\4@=+,;U4X%*87*J\B?:WHN89'0*Y/" KC)UW?>+ MM'#P0&)PL)+$X$?EDFC$BE0EN[1,6TO[&2JZ;CAV#XWR HJ9@KGJ9K+GE=\[ M,=L #P-JV;:C3K5Y5-W50G#@6RI5T7%=VS M/WAQ8ND?4A1 KBJ_:IA6V4+Y MMQL:898E(06A48#H>KH@G<\A@6?;>RO=NEB(_/71-W,W>4HD :HGL80&$X=X M+X<@56S3J63]O<.[ZLSNMN&AX[-+9%JD 14?G0[VOMEWH6Q_"0/'MN7[ONOC M. HM=4S-QS[Q.(;O70+\R)CUX@2*#EAX$6 YO?H,8A_,BV3#O4M%[1(6Z@Y' MJ%\AZ5OF-6R*#7."?Z=.W(^YUP975-?<,/#J&9B1((@"/\ N8S&VK2A4R1PN M)@&U":-V;+V<@;](KK2ONHY,7[&BC'YY$<=<;AAYW1@9<(6C"60MU,B&S;"Y M'>X\CJW+NAO&7CUC.S[W?#"F<10Z'C!V&&,_"AP<&(YK^*9E6_&+8]OW&+N= MYT,N-^S]KMC;XMA6MP$_AKVKNF]UXWSAD?97#/8%W^&JI><&MR;Q4:0/EG75?5U\'Q>B-'78CA.:9E M8E^]06"#QX3#B'K8Y &WXI";0*XOCFR6AM/(,$.M=)9GYRNW#-#?*;+HZW+S MN>8?8_DK> ^ I,+7=-DR)?#RA]);*TA%YC$);9Z/2&V*'"!&WDXY)&#?4JY M%\5>9/(7'_BJ-&.I%)?' D?=B\[FQ-![(,TE$$,7_,W%^:"A36CL$ >3P'&Q M34RB*#?$@>\9;N0PA[@OIO9:YM=1%'WIXC=Q,J7#GWNR;FX6',T9_??WT08E M[1W3@2AH@CY3^77B#/++HT*+;X5>QTRI=LI4H(VC<(0BG34%T_P*-AK7E^7< M2VD2.8()WB:OV\!H0(\#=3>D2@8L8W] R^8C+\J^W[<*!]XUG^B]\4Q* M>YTDK!?<"_]Z='8ZAV86O,ZP:+AY-]7RR'9X0#$A#$R$R ]PZ'D<$R^@\&_@ M$B=8SK'-&JY?-%C')51+WV-82O;G([3ASG7M0#,*H%4O=XF=(BY?,U)$84>*QFIP6\$#*U8((5I0XGD MUR*'=O'X44,:1>I.2559/8G'J&1YF3K*YL6RK6TZCF5/BL0&NH__M-P^!_=\P+T0\JD?1M3 0KH)I M_$)83]Y9Y%>\#*U@&H/*;-'DAH[R:DO@Z4^./6!&+7R;9@HI]Y[[>(EH6?(. M5+O@?62!]X+.,W!=="SLA"<@0G3FN$1G5"3J;57%OU5JN3J.J!A^"/S]J:JI MS1ZHWJE$P![JZGI[B@ Z''PY=9H5F:[F&VMWBEIOP&8#6ZU\>@ , MO(I8:B*NBI7G>I^$%Y!DR".JK#]1Y#IU)5.+HO@J!@%?GB3J V\4\!]PXGQ> M &G^5Z-!B#(74=ZCDFMJMX@B^+R^""0<0C-U40@#_=O09#\)(?1>@.T(JW,% MM5.D[,<$C46*68D4-:F292>@?5MN\!LDWX\!97<&:7W+BI7D?S%[ /#V,3SX.7&XWC*W5_)$;GKNS]BG8 M$)Q![:&RS?/*U,E5S +JT3Y7[&O(>36+E':N.=$"FJM#CDH,OF97=T6'1 MRR2 R^X;K^N8+>\^E-=N/U3X4)F[3@GQ'RGO9P/K1X;5;CSMF=2R_NI.KRU\ M%G9)XZ"'4I6>^9#01MIL8-W ^M9@?3/FQE-%]2H/&9^ %=E:9SVU2N"K"+=? M1K@_ZBK\8[2R>YY7=C3L[:UR,V^B7SG5V<.7G,\\IOIF)-@ZBO\-K!M8GP1K MPWN2<%A:3&S>$DQ)!WWTF*#9./OZT6 7A&-/0)OK1ZG:X%$':)Y^/9I?5M;%^/;T8CZ[>K'S[^ MQ;;![>?15_ 5O8!K-_*?T:T?N@$)8XK N_&7]^#WOS_>@;$[1PL(;HD;+Q". M@ WF4;0<.L[+RTO'F_HX)$$["CDL6#K!M 7Y#$>3WP2V,$!CVN_V?[>[ M[OWZU.T-+WK#P2^=0>_#A[]VN\-N-].,+-?4G\TC\,Y]#W@KUC?&* C6X+./ M(79]&("Q[/0G,,)N!UP' 7CDK4+PB$)$GY'723%7H3<,4QLB2&W: KC(+JT8OR_ M& ;^U$<>\W* N'L4@ )#),7C MT)Y!N-RTF,)PDDB+!US)@13VD*]:$2*W,R//#GN@"'+/5G>SL)(!>I'.2]T+ M)WV8%?4-1K+)&;$)LS%R57"*<"&;AQ^;7[+[O7M0:_#P"R "[/.H*ZSGQ)R;'=28C,Q=E5"#A+O_:*L7^VH M5NHQ+)MS_,+F%\8^"S/U^SK5+@L'!5$H[QA5T*^J5Q4@QB1*^N6WY,WETL=3 MDMYA]_@(#2D)T--ZB0"_^/8XJKK*G BN"":+M<,;.FS"14G@LCT1X&V(/1:! M(C]:V[Q;NDCTL8#/@D]U<:FMU-=#;*OP$\MZ7?Z/;229/65S>8T]\"F!8X%] M _?1R8/DX.,0>??X*KE>4K8#X-2-=^R&:"Q$# U=&+AQ\/WM7M4J;29NRE%3 MQU(NN<3%@8A!^<%^1-/FQCH)A<,Y1=-+BW=B2T@^L7_\;J"(F?;3 MO"2OME&\(979A.0O#./U8D("C8[J\X:48AF_[[)5@F=?F%,H>PG0:*81:F.8 M;]CE/7TB+WC;"&O.&K5L*@Q%;LZM_ MHG6I+_-RC2KY!%E M![: B?<)>YQ ,&Q*JEP;Z_V!L)0H^+>_O"'>UJ"N"C>J[@B[A+(4(YEWR>9R M0V*V=M9&OGZ*H@TI!J/X=<4P1(G*H_;2^U89HQ&+&W7 MQ7JC>#LIWG,4"'*R)35KA2_;= MH5,PP-"2.H_& I+"HKQ13$HQ 0,%'+5^6XS,RGY&*="9_5ET4+N!>3)F1VL2 M&)#@-+"\LU3-C@HG^QK'J-W#)M+F3?-NC@H2V":3[QK2[J;R;1WILVO.)Z" MQ*I]ES#P0/M%) D)4DP@0.NT12&,=M1^@P$X2/V>?Z61]G,WQVDL(]+P2F^T M)XL+D 2A>USKU,_S3[N^6O*V@$Q!K_]N\AY(U";V DY1[4T<,8P*NEY3E8B# MU)6]LLLM'0L)QR4L-B\C.]5!-)]2LMA2(2-[)A4XM#+&KDD#RDIL\@9H^;,V M#:A:>",-J<2@M6E0E7(<:+RG^4?VN8\;:5WU+29!J@HD<:]\4?:&0:H&& M#CN$/5=;/I3?<(M<6/L^-Q45:<-.D0MKWXA*I4:J-=O9L#;-*BM DC9H":\V M%=:5)4EE"T37(2Q84[&2(5&^4TBO TJ6JZ?)AY0@FPJ;-NE:&<'5?MPQECNI M\::+JPJ\C:2MLF?#,A04<_V?^5-C^5-^.L:KYO-QXN!97A.5M6OI_-D1 M'.HZPB+E(SH]L6LQXZD>Z#BB@YM'?YCCX&NJC_)0UY$4@F\A5LM4;?ZD9)5/ M!67:MG1R=SN!5*F>ZH1/3AWP.;.C.+E[X,>TC^R4V='_WH,C.GUVP >4#O,7 M,AS^"<@#/E#XAK_;(,L_O FCLX24DQ_NW ^\-ZUIR;S>$\H"TJ75M<"2O>SQ M"7)I]2T0ATQ!LN3"?.=@IK&019%WE_JE2B7307JH0&R8/J&>O:,C"#=>Z9V] MHN53A'OZ9_>4,3G"0X-3]U E DDXZ^>SL_)DE?#,Q=DS1JY,N.EO9S>5LG/" M1;^<753""0H'_7IVD(F+%%[Z3SZE5TE6ZY>23ZB+Q*UUS\@EU M"?$L_7/RZ;2.\Y;..?GTV<2X2R>=?":]G>>7KCIGTZ;O"M)+)Y]0%S]F2->< M?"J=^Y@B_7+RR;/^>XXD%4\^;1SEO1/O 1 " 0 !A=&]S+3(P,C0P,S$U+FAT;5!+ M 0(4 Q0 ( &5$ XML 14 atos-20240315_htm.xml IDEA: XBRL DOCUMENT 0001488039 2024-03-15 2024-03-15 0001488039 false 8-K 2024-03-15 Atossa Therapeutics, Inc. DE 001-35610 26-4753208 107 Spring Street Seattle WA 98104 206 588-0256 false false false false Common Stock ATOS NASDAQ false